Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...
Asian News International on MSN3d
Amity University Madhya Pradesh honours academic excellence at convocation for class of 2024Amity University Madhya Pradesh hosted its Convocation Ceremony for its class of 2024 in a grand and dignified atmosphere, on ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...
Even worse? It's outfitted with a laughably bad AI-concocted version of the pharmaceutical unicorn Novo Nordisk's logo, complete with incomprehensible gibberish. The company name is clearly ...
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback